A nutraceutical product with original immunostimulant properties produced by the microalga Tetraselmis chuii, already present among those approved for human consumption. The AESAN Scientific Committee issued its initial assessment report (AESAN2013-001, published in the journal of the AESAN Scientific Committee No 18). That report concludes that dried microalgae Tetraselmis chuii meets the criteria for acceptance as a novel food in accordance with Article 3(1) of Regulation (EC) No 258/97.
This semi purified extract of Tetraselmis chuii has been reported to show a similar immunomodulatory profile of Sulfavant. This preparation has an interesting potential to be developed as nutraceutical product with validated, in vitro and in vivo, immunostimulant properties. It may be a valid aid for the prophylaxis and remission of infectious diseases. Moreover it may be useful in case of recurrent upper airways inflammations and acuteness of the flu syndrome.
The global nutraceuticals market is projected to reach USD 578.23 billion by 2025, according to a new report by Grand View Research, Inc. Rising health concerns are likely to drive the product demand over the next eight years.
The market has witnessed an increased focus on the ingredients used for manufacturing nutraceuticals. The demand for natural products is expected to grow at a rapid pace over the next eight years as consumers perceive these products to be healthier and more effective as compared to synthetic products.